Results 291 to 300 of about 74,631 (338)
Automatic speech analysis combined with machine learning reliably predicts the motor state in people with Parkinson's disease. [PDF]
NPJ Parkinsons DisThies T +5 more
europepmc +1 more source
Impact of motor symptom asymmetry on non-motor outcomes in Parkinson's disease: a systematic review. [PDF]
NPJ Parkinsons DisVoruz P, Guérin D, Péron JA.
europepmc +1 more source
Adherence and persistence with istradefylline treatment in patients with Parkinson's disease in the United States. [PDF]
Front PharmacolJoseph R +5 more
europepmc +1 more source
Association of Enterococcus faecalis and tyrosine decarboxylase gene levels with levodopa pharmacokinetics in Parkinson's disease. [PDF]
NPJ Parkinsons DisMiyaue N +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
JAMA: The Journal of the American Medical Association, 1970
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
To the Editor.— The use of levodopa (L-DOPA; dihydroxyphenylalanine) for the treatment of Parkinson's disease has been satisfactorily demonstrated in many cases when other therapeutic measures fail to act. It has been reported in the available literature 1,2 that the administration of levodopa might cause psychiatric symptoms (eg, hallucinations ...
Sidney Merlis, Jose A. Yaryura Tobias
openaire +3 more sources
Journal of Neurology, 2010
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela Contin, Paolo Martinelli
openaire +2 more sources
This paper reviews the clinically relevant determinants of levodopa peripheral pharmacokinetics and main observed changes in the levodopa concentration-effect relationship with Parkinson's disease (PD) progression. Available clinically practical strategies to optimise levodopa pharmacokinetics and pharmacodynamics are briefly discussed.
Manuela Contin, Paolo Martinelli
openaire +2 more sources
Journal of Neurology, 2004
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
The objective of this workshop was to review and discuss the debate on neurotoxicity of levodopa in the treatment of Parkinson's disease (PD) with consideration of preclinical and clinical findings. We concluded that in particular preclinical outcomes of in vitro models of neurodegeneration describe neurotoxic effects of levodopa, whereas trials in ...
Johannes Schwarz +6 more
openaire +4 more sources
Clinical Pharmacology & Therapeutics, 1971
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources
Based on the chemical constitution and metabolism of levodopa as well as on the effects of long‐term therapy in patients with parkinsonism, a hypothesis of pharmacologic activity which clearly differentiates it from conventional antiparkinsonian drugs is proposed.
Simone E. Düby +3 more
openaire +3 more sources